Sign In
Buy CMPS
$12.69
-0.640 (-4.80%)
At Close: Jun 03, 2026
LONDON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental h
Therapy's New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution
01:56pm, Tuesday, 09'th Jan 2024
Though psychedelic therapies and related psychedelic stocks have fallen out of favor recently, there's still tremendous research and insight happening beneath the surface. Even Elon Musk uses ketamine
De-Risking Psychedelics: Compass Pathways, Cybin And Atai
12:00pm, Tuesday, 09'th Jan 2024
Critical catalysts are approaching in the psychedelic sector, with the potential for the first FDA-approved psychedelic therapy by the end of the year.
3 Big New Catalysts for Psychedelics Stocks in 2024
11:47am, Monday, 08'th Jan 2024
Psychedelics stocks could be buoyed by a few positive events soon. The government is now funding the study of certain psychedelics.
Investing in Mental Health: 3 Stocks in the Wellness Space
04:09pm, Tuesday, 05'th Dec 2023
Mental health stocks are democratizing access to mental health services for millions across the globe. The lack of access to qualified counselors is a significant hurdle for people to get the help the
Compass Pathways to participate in upcoming Evercore investor conference
08:00am, Friday, 24'th Nov 2023
LONDON, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced
COMPASS Pathways plc (CMPS) Q3 2023 Earnings Call Transcript
11:51am, Saturday, 04'th Nov 2023
COMPASS Pathways plc (NASDAQ:CMPS ) Q3 2023 Results Conference Call November 2, 2023 8:00 AM ET Company Participants Stephen Schultz - SVP, IR Kabir Nath - CEO Mary-Rose Hughes - Interim CFO Dr. Guy G
COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results on November 2, 2023
04:01pm, Tuesday, 24'th Oct 2023
LONDON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced
Don't Miss the Boom: 3 Psychedelic Stocks Set to Explode Higher
03:17pm, Wednesday, 27'th Sep 2023
Psychedelic stocks are on the rise. Despite the stigma surrounding psychedelics for personal use, controlled medical experiments indicate their usefulness for treating a variety of conditions.
COMPASS Pathways to participate in upcoming September investor conferences
04:30pm, Tuesday, 29'th Aug 2023
LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced
3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street
07:50am, Saturday, 26'th Aug 2023
Cathie Wood is an icon in the world of disruptive tech. Her firm ARK Invest holds positions in Beam Therapeutics, COMPASS Pathways, and 908 Devices.
COMPASS Pathways plc (CMPS) Q2 2023 Earnings Call Transcript
10:38pm, Saturday, 05'th Aug 2023
COMPASS Pathways plc (NASDAQ:CMPS ) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Stephen Schultz - Senior Vice President of Investor Relations Kabir Nath - Chief Exe
COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023
08:32am, Monday, 31'st Jul 2023
LONDON, July 31, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced
This Unexpected Development Is Yet Another Green Flag for Compass Pathways Stock
10:15am, Friday, 28'th Jul 2023
COMP360 appears to be compatible with certain antidepressant medications. That's contrary to some prior assumptions, so it's a pleasant surprise.
Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.
06:00pm, Sunday, 16'th Jul 2023
Alex Carchidi returns to update investors on the psychedelics industry. Collapse, consolidation, and why you shouldn't bet on just 1 stock.
